Sledovať
XUAN ZHANG
XUAN ZHANG
Professor, Shanghai Institute of Materia Medica, CAS
Overená e-mailová adresa na: simm.ac.cn - Domovská stránka
Názov
Citované v
Citované v
Rok
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ...
Nature medicine 25 (12), 1938-1947, 2019
5292019
Discovery of piperlongumine as a potential novel lead for the development of senolytic agents
Y Wang, J Chang, X Liu, X Zhang, S Zhang, X Zhang, D Zhou, G Zheng
Aging (Albany NY) 8 (11), 2915, 2016
2732016
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
Y He, X Zhang, J Chang, HN Kim, P Zhang, Y Wang, S Khan, X Liu, ...
Nature communications 11 (1), 1996, 2020
2242020
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
S Khan, Y He, X Zhang, Y Yuan, S Pu, Q Kong, G Zheng, D Zhou
Oncogene 39 (26), 4909-4924, 2020
2062020
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity
D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ...
Nature communications 12 (1), 6896, 2021
1222021
Oxidation resistance 1 is a novel senolytic target
X Zhang, S Zhang, X Liu, Y Wang, J Chang, X Zhang, SG Mackintosh, ...
Aging cell 17 (4), e12780, 2018
1192018
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
Y He, R Koch, V Budamagunta, P Zhang, X Zhang, S Khan, D Thummuri, ...
Journal of hematology & oncology 13, 1-13, 2020
1012020
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Y He, S Khan, Z Huo, D Lv, X Zhang, X Liu, Y Yuan, R Hromas, M Xu, ...
Journal of Hematology & Oncology 13, 1-24, 2020
972020
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs
Y Xiao, J Wang, LY Zhao, X Chen, G Zheng, X Zhang, D Liao
Chemical Communications 56 (68), 9866-9869, 2020
942020
Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors
X Zhang, Y Kong, J Zhang, M Su, Y Zhou, Y Zang, J Li, Y Chen, Y Fang, ...
European journal of medicinal chemistry 95, 127-135, 2015
922015
Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity
Y He, W Li, D Lv, X Zhang, X Zhang, YT Ortiz, V Budamagunta, J Campisi, ...
Aging cell 19 (3), e13117, 2020
912020
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
X Zhang, D Thummuri, X Liu, W Hu, P Zhang, S Khan, Y Yuan, D Zhou, ...
European journal of medicinal chemistry 192, 112186, 2020
852020
The discovery of colchicine-SAHA hybrids as a new class of antitumor agents
X Zhang, J Zhang, L Tong, Y Luo, M Su, Y Zang, J Li, W Lu, Y Chen
Bioorganic & medicinal chemistry 21 (11), 3240-3244, 2013
792013
Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X L
X Zhang, D Thummuri, Y He, X Liu, P Zhang, D Zhou, G Zheng
Chemical Communications 55 (98), 14765-14768, 2019
762019
Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation
X Liu, Y Wang, X Zhang, Z Gao, S Zhang, P Shi, X Zhang, L Song, ...
Bioorganic & medicinal chemistry 26 (14), 3925-3938, 2018
652018
Assays and technologies for developing proteolysis targeting chimera degraders
X Liu, X Zhang, D Lv, Y Yuan, G Zheng, D Zhou
Future Medicinal Chemistry 12 (12), 1155-1179, 2020
622020
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
X Zhang, Y He, P Zhang, V Budamagunta, D Lv, D Thummuri, Y Yang, ...
European journal of medicinal chemistry 199, 112397, 2020
552020
The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase
X Zhang, B Bao, X Yu, L Tong, Y Luo, Q Huang, M Su, L Sheng, J Li, ...
Bioorganic & Medicinal Chemistry 21 (22), 6981-6995, 2013
502013
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
D Thummuri, S Khan, PW Underwood, P Zhang, J Wiegand, X Zhang, ...
Molecular cancer therapeutics 21 (1), 184-192, 2022
462022
Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
R Kolb, U De, S Khan, Y Luo, MC Kim, H Yu, C Wu, J Mo, X Zhang, ...
Nature communications 12 (1), 1281, 2021
442021
Systém momentálne nemôže vykonať operáciu. Skúste to neskôr.
Články 1–20